Hs746T/CR
CBP60481DR-2
询 价
留 言
产品描述
产品数据库
| I. Background | |
| Crizotinib 作为全球首个靶向 ALK/ROS1/MET 的多激酶抑制剂，显著改善晚期 ALK 阳 性非小细胞肺癌（NSCLC）患者生存，但其耐药机制主要涉及靶点二次突变（如 ALK L1196M 守门突变、G1202R 溶剂前沿突变直接阻碍药物结合）、旁路信号激活 （EGFR/KIT 扩增或 KRAS 突变驱动替代通路）、药代动力学逃逸（血脑屏障穿透不足致 脑转移进展），以及下游信号重塑（如 STAT3/SFK 持续激活维持肿瘤生存）。 | |
| II. Introduction | |
| Host Cell: | Hs746T/CR |
| Culture Medium: | DMEM+10%FBS+500 nM Crizotinib |
| Gi50 on Hs746T： | 10.7nM |
| Gi50 on Hs746T/CR： | ＞1000nM |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen |
| III. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | stomach; derived from metastatic site: left leg |
| Disease: | gastric carcinoma |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
|
IV.Representative DATA |
|
|
Figure 1. CTG Proliferation Assay of Hs746T CR (Crizotinib Resistant). |
|
